Craig-Hallum raised the firm’s price target on Grace Therapeutics (GRCE) to $11 from $8 and keeps a Buy rating on the shares following the company’s Phase 3 STRIVE-ON data for GTX-104, which showed a numerical advantage on the primary and positive trends on many secondaries. The firm cites now 90% probability of success in the model as the company is entering the regulatory phase.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE: